Mycenax and RIN sign license agreement to advance ADC development using RIN’s proprietary linker technology

CAR-T Digest - August 2020

31 October 2025: Mycenax and RIN sign license agreement to advance ADC development using RIN’s proprietary linker technology

Mycenax Biotech Inc., a Taiwan-based biologics CDMO, entered into a License Agreement with Japan’s RIN Institute Inc., granting Mycenax global rights to use RIN’s proprietary Val-Leu-Lys (VLK) linker technology in its CDMO services
The VLK linker has shown strong anti-tumor efficacy and exceptional serum stability, making it a valuable component for developing next-generation ADCs with enhanced therapeutic performance
It enables dual mechanisms of cytotoxicity acting within the tumor microenvironment and improving ADC internalization, which collectively contributes to greater precision and potency against cancer cells
Through this collaboration, Mycenax strengthens its ADC development capabilities and positions itself as a competitive partner for global pharmaceutical companies seeking differentiated linker technologies
This agreement follows a Letter of Intent signed in April 2025, marking a strategic step toward long-term cooperation between Mycenax and RIN Institute to drive innovation in ADC therapeutics